FRC
FRC Logo
Sign InGet Access

Connect With Us

Stay updated with our latest research and insights

Fundamental Research Corp Logo

Highly ranked equity research firm providing institutional grade tools and analysis to all investors worldwide. Trusted by global investors for over 20+ years.

20+ Years

Policies

  • Privacy Policy
  • Terms of Service
  • Disclaimer

Company

  • About Us
  • Our Team
  • Contact Us

Resources

  • Videos
  • Research Reports
  • FAQ

© 2026 Fundamental Research Corp. All Rights Reserved.

Professional investment research since 2003

Home
Research
Get Access
Sign In
Acrivon Therapeutics, Inc. Common Stock Stock AnalysisComprehensive stock analysis for Acrivon Therapeutics, Inc. Common Stock (ACRV) including live price, Snowflake performance metrics, financial statements, and investment research.Stock AnalysisACRV
ACRV
Acrivon Therapeutics, Inc. Common Stock
  • Company Overview
  • FRC Research
  • Financial Data
  • Peer Comparison
  • Ownership & News
ACRV
Home🔹Stocks🔹Acrivon Therapeutics, Inc. Common Stock

Acrivon Therapeutics, Inc. Common Stock

ACRV•NASDAQ

Acrivon Therapeutics, Inc. Common Stock

ACRV•NASDAQ
Market cap
$65.91M
Sentiment

Your view on ACRV

Mkt Cap
$65.91M
Sentiment
Your view
ACRV
Acrivon Therapeutics, Inc. Common Stock
  • Company Overview
  • FRC Research
  • Financial Data
  • Peer Comparison
  • Ownership & News
ACRV
Company Overview

Overview

What the company does, where it operates, and who runs it.

About Acrivon Therapeutics, Inc. Common Stock

Industry
Biotechnology
Sector
Healthcare
CEO
Peter Blume-Jensen
Headquarters
480 Arsenal Way, Watertown, MA, US
Industry
Biotechnology
Sector
Healthcare
CEO
Peter Blume-Jensen
Headquarters
480 Arsenal Way, Watertown, MA, US
Description

Acrivon Therapeutics, Inc., a clinical stage biopharmaceutical company, engages in developing oncology medicines for the patients whose tumors are predicted to be sensitive to each specific medicine by utilizing its proteomics-based patient responder identification platform. The company's Acrivon Predictive Precision Proteomics, a precision medicine platform enables the creation of drug specific proprietary OncoSignature companion diagnostics that are used to identify the patients to benefit from its drug candidates. Its lead clinical candidate is ACR-368, a selective small molecule inhibitor targeting CHK1 and CHK2, which is in a potentially registrational Phase 2 trial across various tumor types, including platinum-resistant ovarian, endometrial, and bladder cancer. The company is also developing its preclinical stage pipeline programs targeting critical nodes in the DNA damage response and cell cycle regulation pathways, such as WEE1, a protein kinase and PKMYT1, a protein serine/threonine kinase. The company was incorporated in 2018 and is based in Watertown, Massachusetts.

Infographics

Visual summary of the business at a glance.

FRC Research

Media

Videos and interviews covering the company.

Financial Data

Stock Data

Price chart, volume, and trading data.

Fair Value

What FRC thinks the stock is worth vs. the current price.

Financial Ratios

Profitability, returns, valuation, and leverage ratios.

Dividend Analysis

Yield, payout ratio, and dividend coverage metrics.

Earnings Analysis

EPS history, beat rate, and upcoming earnings reports.

Financial Statements

Income statement, balance sheet, and cash flow statements.

Peer Comparison

Comparables

List of peer companies in the same industry.

Ownership & News

Institutional Ownership

Which funds and firms own the stock.

Insider Trading

Recent buying and selling by company executives.

Senate Trading

U.S. Senator disclosures filed under the STOCK Act.

News

Latest headlines and market coverage.

News

Latest Market News